Skip to main content

Dihexa vs Humanin

Both Dihexa and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

Dihexa

Evidence C

Dihexa (PNB-0408)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

View full Dihexa profile →

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

Side-by-Side

AttributeDihexaHumanin
Evidence GradeCB
FDA StatusNot FDA-approved — research compound (HGF/c-Met-mimetic)Not FDA-approved — mitochondrial-derived peptide research compound
Typical Dose8–45 mg orally daily (research-only)Research range: 0.5–1 mg subcutaneous (rare clinical use)
Clinics Indexed105
Categoriescognitive, neuroprotectionmitochondrial, longevity, neuroprotection

Key reported benefits — Dihexa

  • Synaptogenesis (preclinical)
  • Memory improvement (animal)
  • Possible Alzheimer's relevance

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons